https://doi.org/10.55788/411391f4
The phase 2 NADIM trial (NCT03081689) investigated the safety and efficacy of neoadjuvant chemotherapy plus nivolumab in 46 patients with stage IIIA, resectable NSCLC. The positive results of this trial were previously published in The Lancet Oncology [2]. Through RNA sequencing, the current analysis aimed to identify biomarkers of disease progression in patients that had received surgery in this trial (n=36). Ms Marta Casarrubios (Hospital Universitario Puerta de Hierro-Majadahonda, Spain) presented the findings.
The analysis identified 22 differentially expressed genes between patients achieving a CPR and those who did not achieve CPR. The majority of these genes were associated with proliferation and tumour marker genes and were upregulated in patients who did not achieve CPR. Furthermore, non-CPR tumours appeared to have a higher proportion of follicular T-helper cells (P=0.025), whereas CPR tumours showed upregulation of antigen processing, T-cell receptor co-expression, and lymphocyte infiltration pathways. In total, 10 genes were differentially upregulated in tumours from patients with disease progression, mostly being genes related to tumour markers or type 1 interferon signalling. Finally, in the non-CPR population, upregulation of AKT1 and a higher proportion of activated neutrophil dendritic cells were associated with a reduced progression-free and overall survival.
- Casarrubios M, et al. Tumor Bulk-RNA seq identifies patients at high risk of progression in non-complete pathological responders from NADIM trial. 03, WCLC 2022, Vienna, Austria, 06–09 August.
- Provencio M, et al. Lancet Oncology. 2020;21(11):1413-1422
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC Next Article
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC? »
« NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC Next Article
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC? »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles
November 8, 2019
EGFR TKI retreatment effective after earlier discontinuation
November 21, 2018
Angiogenic and stromal biomarkers in malignant mesothelioma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy